News | October 27, 2025
CPHI & PMEC India 2025 to see participation of 2,000+ exhibitors
The event will be attended by 35,000+ industry professionals
The event will be attended by 35,000+ industry professionals
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Adverum's lead program, Ixo-vec, is a Phase 3 gene therapy designed to treat vision loss associated with wet age-related macular degeneration with a single intravitreal dose
Telangana aims to increase the value of the Life Sciences economy from US$ 80 billion to US$ 250 billion by 2030
Bioconjugation capability to complement commercial payload, linker, and monoclonal antibody services
Efdoralprin Alfa was well tolerated, with a safety profile comparable to plasma-derived therapy
Nicardipine Hydrochloride in 0.9% Sodium Chloride Injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or desirable
Glenmark’s Ropivacaine Hydrochloride Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug Naropin Injection of Fresenius Kabi USA
The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Subscribe To Our Newsletter & Stay Updated
